psychedelics investing Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
psychedelics investing Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
psychedelics investing Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
psychedelics investing Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
psychedelics investing Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
psychedelics investing Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635
psychedelics investing Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
